Your browser doesn't support javascript.
loading
URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers.
Ding, Zhiwen; Pan, Yufei; Shang, Taiyu; Jiang, Tianyi; Lin, Yunkai; Yang, Chun; Pang, Shujie; Cui, Xiaowen; Wang, Yixiu; Feng, Xiao Fan; Xu, Mengyou; Pei, Mengmiao; Chen, Yibin; Li, Xin; Ding, Jin; Tan, Yexiong; Wang, Hongyang; Dong, Liwei; Wang, Lu.
Afiliação
  • Ding Z; Department of Hepatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
  • Pan Y; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Shang T; School of Life Sciences, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, 200438, P. R. China.
  • Jiang T; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Lin Y; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Yang C; Children's Hospital of Soochow University, Suzhou, 215025, P. R. China.
  • Pang S; Department of Hepatic Surgery V, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, P. R. China.
  • Cui X; Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, P. R. China.
  • Wang Y; Department of Hepatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
  • Feng XF; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Xu M; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Pei M; Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, P. R. China.
  • Chen Y; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Li X; Department of Integrated Chinese and Western Medicine, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, P. R. China.
  • Ding J; Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, 200438, P. R. China.
  • Tan Y; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China.
  • Wang H; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China. hywangk@vip.sina.com.
  • Dong L; School of Life Sciences, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, 200438, P. R. China. hywangk@vip.sina.com.
  • Wang L; National Center for Liver Cancer, Naval Medical University, Shanghai, 201805, P. R. China. dlw@smmu.edu.cn.
Nat Commun ; 14(1): 6269, 2023 10 07.
Article em En | MEDLINE | ID: mdl-37805657
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Ferroptose / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Ferroptose / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article